ACLX
$114.52
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, wh...
Recent News
Gilead Sciences Conference: 6-Month HIV Regimens, 12-Month PrEP, Livdelzi Expansion, Oncology Push
Gilead Sciences (NASDAQ:GILD) executives outlined the company’s approach to next-generation HIV medicines, ongoing commercialization efforts in liver disease, and a broad slate of oncology and inflammation programs during a discussion hosted by Leerink Partners analyst Daina Graybosch. HIV: Moving
Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth
Gilead Sciences (NASDAQ:GILD) Chief Financial Officer Andrew Dickinson told investors at the Barclays conference that the company is entering what he described as “the beginning of a long cycle,” supported by recent launches, a broadening pipeline, and continued operating discipline. Dickinson said
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally
Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally
This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.